Oct 27, 2026 Partner results reiterate the Q4 iLet integration objective Headline · Source: company release

Nasdaq: $SENSDated financial statementsOperating and funding watchpointsExecution risk

SENS Stock Hub: Senseonics News, Eversense 365 and iLet Integration

Eversense 365 revenue growth and the planned iLet integration broaden the commercial opportunity. Operating cash use, debt and additional shares remain the counterweight. The October 30 regular-session close was $9.51 (-2.46% versus October 29).

Last updated: November 2, 2026Market reference: October 30, 2026 regular-session closeFinancial period: June 30, 2026; common shares July 31, 2026Research archive: October 27, 2026; currency USD unless stated

Full research report · PDF

Senseonics Holdings ($SENS), research as of October 27, 2026

17 pages covering the dated business, operating milestones, financial resources, capital structure, risks, scenarios, sources and FAQ. This is a dated research snapshot; the hub follows later developments. For personal use only: redistribution prohibited.

Get the report (PDF)

Next announced company event

November 9, 2026 · results after close, call 4:30 p.m. ET

Senseonics scheduled third-quarter results for November 9 with a 4:30 p.m. ET call. The iLet–Eversense 365 commercial launch remains a separate Q4 2026 partner expectation. Primary source

Beta Bionics reported on October 27 and reiterated the Q4 integration launch expectation; that report is a past checkpoint, not the next event. Launch completion is not established by the guidance. Primary source

Senseonics Holdings SENS daily stock chart — Daily chart $SENS. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

SENS stock at a glance

Close · October 30, 2026

$9.51

Regular session; -2.46% versus $9.75 on October 29.

Common shares · July 31, 2026

52,874,053

Q2 10-Q cover; penny warrants are separate from issued shares.

Q2 2026 revenue

$14.483M

Up 117.8% versus Q2 2025; reported August 6.

Liquidity · June 30, 2026

$142.659M

Cash and equivalents plus marketable securities; excludes restricted cash.

H1 2026 operating cash use

$62.163M

Six-month cash-flow statement; no October cash balance is implied.

2026 revenue guidance · August 6

$62M–$66M

Company outlook, not reported full-year results.

Q2 2026 gross margin

59.1%

Quarter ended June 30, 2026.

Hercules principal · June 30

$55.0M

Borrowed principal; conditional undrawn tranches are separate.

Where Senseonics Holdings stands now

June 30 cash and equivalents of $44.753 million plus $97.906 million of investments total $142.659 million, excluding $0.315 million restricted cash. First-half operations used $62.163 million while financing supplied $112.062 million. Hercules principal was $55 million; future undrawn tranches are conditional. Q2 revenue growth and a 59.1% gross margin coexist with a $35.988 million operating loss. Primary source

The operating evidence and financing conditions remain separate tests. A partner launch objective is not a completed launch or an incremental sales figure. Freedom remains investigational and early feasibility is not pivotal evidence.

The constructive case

The commercial transition has improved reported revenue and gross margin, while operating losses remain. Revenue more than doubled year on year, the United States went from $4.946M to $12.572M in the year-over-year Q2 comparison, and gross margin reached 59.1% — above the range the company had guided for the second quarter running. Management responded by raising both guidance lines at once, revenue to $62M–$66M and gross margin to 58%–61%, which is a different signal from reaffirming them. The U.S. commercial transition became effective January 1; the company reported the European commercial handover in June, while remaining support work in Italy and Germany was targeted for Q3. There is $142.7M of unrestricted cash and marketable securities, no convertible notes, no going-concern language, and a director bought stock on the open market in August outside any trading plan.

The cautious case

The share count went from 41,265,778 to 52,864,750 in six months, up 28.1%, and the authorised count was lifted from 70 to 140 million in May. The at-the-market programme still has $90.8M of capacity, there are 12,197,554 pre-funded warrants at nominal exercise prices, and 8,654,892 further securities sit outside the loss-per-share calculation as anti-dilutive. Operations consumed $62.163M of cash over the half against $142.7M on hand, and the $55.0M Hercules facility had a reported 9.90% rate under a variable-rate formula, a 13.80% effective rate and a minimum-cash covenant. Selling and administrative spending tripled to $32.908M, so the operating loss widened even as revenue doubled, and the nearest dated milestone in the pipeline — the Gemini pivotal — has an estimated primary completion of December 2027.

Latest Senseonics Holdings news

Oct 27, 2026

Partner results reiterate the Q4 iLet integration objective

Beta Bionics reiterated an expected Q4 2026 commercial launch for the integrated iLet and Eversense 365 system. The earnings event has occurred; the launch remains guidance rather than an established completed launch.

Company announcement

Oct 26, 2026

First-in-human study of Freedom, the CGM designed with no on-body component

Senseonics started the first-in-human clinical study of Freedom, an investigational one-year CGM built on the Eversense 365 sensing technology with an integrated battery and embedded Bluetooth, designed to communicate directly with a mobile device without an external on-body transmitter. It is an early feasibility study of clinical safety and device functionality, including the direct Bluetooth link. It follows preclinical work completed in the second quarter of 2026, in which the preferred antenna design achieved 100% communication success within the target distance across more than 18,500 data points over about seven weeks, according to the company. Senseonics expects to start a pivotal study in 2027 and targets a potential commercial launch in 2028; both are company objectives.

Company announcement

Oct 22, 2026

Stifel and Canaccord investor conferences in November

Senseonics management will hold a fireside chat at the Stifel 2026 Healthcare Conference in New York on Tuesday, November 10, 2026 at 3:20 p.m. ET, with one-on-one meetings, and will present at the 20th Annual Canaccord Genuity MedTech, Diagnostics & Digital Health Forum in New York on Wednesday, November 11 at 10:30 a.m. ET. Both are after the November 9 third-quarter report; webcasts are on the investor relations site.

Company announcement

Oct 21, 2026

Third-quarter results on November 9

Senseonics will release its third-quarter 2026 financial results after the U.S. market close on Monday, November 9, 2026, and will hold a conference call at 4:30 p.m. ET the same day, with a concurrent webcast on its investor relations site. Company release

Company announcement

Sep 22, 2026

Beta Bionics expects the iLet launch with Eversense 365 in Q4

Beta Bionics announced the agreement to integrate both the iLet Bionic Pancreas and its mint automated insulin delivery system with Eversense 365. It expects the commercial launch of the integrated iLet and Eversense 365 system in the fourth quarter of 2026 ; the mint integration has no date. Beta Bionics reports third-quarter results on October 27, 2026.

Company announcement

Sep 14, 2026

Senseonics announces the Beta Bionics partnership

Senseonics announced a strategic partnership to integrate Eversense 365 with the iLet Bionic Pancreas, which adapts insulin delivery without carbohydrate counting. Development completion and commercial launch are planned for Q4 2026 , subject to testing, validation and applicable regulatory requirements. The release gives no contract value and does not change the 2026 revenue guidance.

Company announcement

SENS stock catalysts and dated watchpoints

November 9, 2026 · 4:30 p.m. ET — Results after the market close and company conference call. Company-announced
Q4 2026 — Expected commercial launch of the integrated iLet and Eversense 365 system, subject to the required steps. Partner guidance, not completed launch
November 10 / 11, 2026 — Stifel and Canaccord investor presentations. Company-announced
2027 / 2028 — Freedom pivotal study and potential commercial launch targets respectively. Company development objectives

Primary source · Primary source · Primary source

Financial Deep Dive: Growth Is Real, Operating Leverage Is Not Yet Proven

The June 2026 Form 10-Q adds an important revenue-mix distinction: Ascensia accounted for 12.5% of second-quarter revenue, down from 52.0% a year earlier, while sales under consignment arrangements represented 57.7% of revenue versus 40.9%. These are customer and distribution-channel measures, not direct measures of end-patient demand. Senseonics Form 10-Q for the quarter ended June 30, 2026.

Revenue growth has accelerated with the Eversense 365 launch and increased U.S. adoption. Full-year 2025 revenue reached $35.3 million, up 57% from $22.5 million in 2024. U.S. revenue increased to $27.9 million, while revenue outside the U.S. was $7.4 million. Q1 2026 revenue was $11.7 million, including $9.3 million in the U.S. and $2.4 million internationally. The second quarter took that to $14.5 million, approximately 120% above the $6.6 million of the year-earlier quarter, and the company describes it as the highest quarterly shipment volume in its history.

Cash Runway, Debt and Dilution: The Most Important Risk Section

At December 31, 2025, cash, cash equivalents and investments totaled $94.3 million, according to the March 2, 2026 results release. This historical liquidity figure includes investments and is not a cash-only balance or an October balance. Senseonics press release, March 2, 2026.

Senseonics ended March 2026 with $64.6 million of cash, cash equivalents and investments and approximately $35.2 million of debt. In May, the company completed a $92 million gross underwritten offering and reported approximately $86 million of net proceeds. It also amended the Hercules facility to provide total borrowing capacity of up to $140 million.

Merlintrader Health Score · $SENS

2.55out of 5

Balance sheet and runway · 30%2.5

$142.7 million of unrestricted cash, cash equivalents and marketable securities at June 30, 2026, against $62.163 million consumed by operations over the six months. The Hercules facility carries $55.0 million of principal at 9.90%, a 13.80% effective rate, a minimum-cash covenant and a September 3, 2029 maturity. The company states its resources are sufficient for at least twelve months and raises no going-concern doubt.

Catalyst · 30%2.5

The iLet integration remains a Q4 2026 partner objective, reiterated October 27. The next Senseonics results are November 9; Freedom remains in early feasibility. Primary source

Dilution · 20%1.5

This is the weak pillar. Shares outstanding rose 28.1% in six months, from 41,265,778 to 52,864,750, authorised shares doubled to 140 million in May, the at-the-market programme retains $90.8 million of capacity, 12,197,554 pre-funded warrants sit at nominal exercise prices and a further 8,654,892 securities are excluded from loss per share as anti-dilutive.

Liquidity · 10%3.0

Historical trading-access assessment retained. The October 30, 2026 regular-session close was $9.51; price alone does not establish spreads, depth or future turnover.

Execution · 10%4.5

Revenue more than doubled year on year, United States revenue went from $4.946 million to $12.572 million in the year-over-year Q2 comparison, gross margin reached 59.1%, and both the revenue and gross-margin guidance ranges were raised rather than reaffirmed. The European commercial handover was reported complete in June, with remaining support activities described separately and a director reported an open-market stock purchase in August.

Assessed October 4, 2026. Weighted calculation: 2.5×30% + 2.5×30% + 1.5×20% + 3.0×10% + 4.5×10% = 2.55. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.

Red flags

Financial balances retain their reporting dates; they are not current cash.
Company targets and guidance do not establish completed execution or a regulatory outcome.
Financing, obligations and changes in the share count affect per-share economics.

SENS Stock FAQ: Senseonics Holdings Questions Answered

What is the next SENS stock catalyst?

Senseonics’ next scheduled financial checkpoint is its Q3 2026 report on November 9, 2026, after the market closes, with a 4:30 p.m. ET call. Separately, Beta Bionics reiterated on October 27 that commercial launch of the integrated iLet–Eversense 365 system was expected in Q4 2026, rather than announcing a completed launch. Company results notice. October 27 partner update.

Is Senseonics Eversense 365 FDA approved?

Eversense 365 received FDA device clearance on September 16, 2024; the precise U.S. regulatory term is cleared. Senseonics’ newer Freedom system remained investigational in its October 26, 2026 announcement of a first-in-human feasibility study. Freedom is designed to remove the on-body transmitter; the company targets a pivotal study in 2027 and a potential launch in 2028. FDA Eversense 365 clearance. October 26 Freedom update.

How much cash does Senseonics have, and how long is it funded?

Senseonics held $142.659 million of unrestricted cash, equivalents and investments at June 30, 2026, while management expected its operating plan to be funded into 2028. First-half operations used $62.163 million of cash and Hercules loan principal was $55 million. The funding outlook incorporates expected operating cash flows. June 10-Q, liquidity and debt.

How many SENS shares and pre-funded warrants are outstanding?

Senseonics reported 52,874,053 common shares outstanding on July 31, 2026, compared with 41,265,778 at December 31, 2025; its June 10-Q separately disclosed 12,197,554 penny-warrant shares. Those included 8 million May pre-funded warrants. ATM capacity remaining at June 30 was $90.8 million. Warrants and potential future ATM sales can increase the issued common share count. June 10-Q cover and capital structure.

When does Senseonics report Q3 2026 earnings?

Senseonics will release Q3 2026 results after the U.S. market closes on November 9, 2026. Its conference call is scheduled for 4:30 p.m. ET that day, according to the October 21 announcement. Company earnings announcement.

What does Senseonics Holdings do?

Senseonics develops and commercializes long-term implantable continuous glucose monitoring systems for people with diabetes. Eversense 365 combines an implanted sensor, removable on-body transmitter and mobile app. Its development pipeline includes Gemini and Freedom, intended to expand the capabilities and convenience of its monitoring technology. Company and technology description.

What is Senseonics’ revenue guidance for 2026?

On August 6, 2026, Senseonics raised full-year revenue guidance to $62 million–$66 million from $60 million–$64 million. It also raised its gross-margin outlook to 58%–61% from 55%–58%. These are management’s annual forecasts, following Q2 revenue of approximately $14.5 million. August 6 results and outlook.

When does Senseonics’ Gemini pivotal trial finish?

As of November 2, 2026, the Gemini registry listed estimated primary completion in December 2027 and estimated study completion in May 2028. The trial evaluates performance and safety of the Eversense Gemini system with a flash-glucose feature. These are registry estimates, rather than announced FDA decision dates. Gemini trial registry.

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent analysis. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $SENS or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.

Senseonics faces commercial adoption, reimbursement, manufacturing, competition and financing risks alongside clinical and regulatory uncertainty for products in development. Existing clearance does not guarantee sales growth or clearance of another device. Debt obligations, cash consumption and further equity issuance can materially affect shareholder value. Readers are responsible for their decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.

This coverage is for informational and educational purposes only. It is not financial advice, investment research, medical advice or a recommendation to buy, sell or hold any security. Senseonics is a small-cap medical-technology company exposed to commercial adoption risk, reimbursement risk, procedure-capacity constraints, competition, operating losses, debt, financing needs, dilution, regulatory requirements, product-performance risk and high share-price volatility. Forward-looking statements, company guidance, pipeline timelines and management runway estimates may change. Readers should review original SEC filings, FDA documentation, company releases and professional medical guidance before making decisions.

SENS Stock Hub: Senseonics News, Eversense 365 and iLet Integration

SENS stock at a glance